uniQure FY2026 EPS Estimate Lowered by Leerink Partnrs

uniQure (NASDAQ:QURE - Free Report) - Research analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for shares of uniQure in a research note issued on Tuesday, April 29th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings of ($2.61) per share for the year, down from their previous estimate of ($0.98). The consensus estimate for uniQure's current full-year earnings is ($3.75) per share.

A number of other research firms have also issued reports on QURE. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of uniQure in a report on Monday, April 21st. StockNews.com raised uniQure to a "sell" rating in a research note on Tuesday, March 11th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $24.00 price objective on shares of uniQure in a research report on Tuesday, January 21st. Wells Fargo & Company lowered their price objective on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. Finally, Chardan Capital reissued a "buy" rating and issued a $38.00 price target on shares of uniQure in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $38.80.

uniQure Price Performance

QURE stock traded down $4.06 during trading on Thursday, hitting $11.83. The company had a trading volume of 4,261,533 shares, compared to its average volume of 1,798,998. The firm has a market capitalization of $648.00 million, a price-to-earnings ratio of -2.43 and a beta of 0.10. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The business has a 50 day moving average of $12.24 and a 200 day moving average of $11.99. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 6,717 shares of the business's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the sale, the chief executive officer now directly owns 580,795 shares in the company, valued at approximately $6,574,599.40. The trade was a 1.14 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Christian Klemt sold 10,438 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the transaction, the chief financial officer now owns 217,730 shares of the company's stock, valued at approximately $2,240,441.70. This represents a 4.57 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 90,830 shares of company stock valued at $961,401. 4.74% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently made changes to their positions in the business. Avoro Capital Advisors LLC bought a new stake in shares of uniQure during the fourth quarter valued at approximately $38,410,000. Franklin Resources Inc. raised its stake in shares of uniQure by 33.1% in the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock valued at $35,103,000 after acquiring an additional 494,726 shares during the period. Point72 Asset Management L.P. increased its stake in uniQure by 81.3% in the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock worth $31,282,000 after buying an additional 794,459 shares during the period. Integral Health Asset Management LLC raised its holdings in shares of uniQure by 175.0% in the 4th quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock valued at $19,426,000 after purchasing an additional 700,000 shares in the last quarter. Finally, RTW Investments LP grew its position in shares of uniQure by 8,936.3% in the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock worth $15,958,000 after buying an additional 893,625 shares during the last quarter. Institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.